Archives202520242023202220212020201920182017201620152014201320122011 May 04, 2022UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION Read More April 13, 2022UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More February 07, 2022LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently Read More January 10, 2022TR1 – Avion Pharmaceuticals – Major Holdings in Shares (10 January 2022) Read More January 10, 2022TR1 – Luca Associates – Major Holdings in Shares (4 January 2022) Read More December 24, 2021TR1 – Lanstead – Major Holding in Shares Read More December 20, 2021Subscriptions and Placing to raise £3.55 million; Sharing Agreement; to fund Investment in R&D pipeline • Company’s Partner Alora and two longstanding investors including Lanstead to participate at an Issue price of 11p – 80% premium to current share price Read More November 29, 2021Collaboration with Imperial College London Read More November 18, 2021CORPORATE UPDATE – The Evolution of ImmuPharma Read More October 01, 2021EURONEXT DELISTING – Date: 18 October 2021 Read More September 30, 2021Prof. Sylviane Muller awarded prestigious Legion d’honneur.’ Read More September 29, 2021Corporate Update Read More 1…678910…24
April 13, 2022UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More
February 07, 2022LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently Read More
December 20, 2021Subscriptions and Placing to raise £3.55 million; Sharing Agreement; to fund Investment in R&D pipeline • Company’s Partner Alora and two longstanding investors including Lanstead to participate at an Issue price of 11p – 80% premium to current share price Read More
